Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

Zacks Investment Research News Agency

3 hours ago•Zacks Investment Research

Stocks Medium Importance Neutral

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.

Related Symbols 1

A ANGO ANGO

Source: Zacks Investment Research

Visit Source

0 0 0

Comment

Comments

No comments yet

Be the first person to comment on this news item.

Category Stocks

Source Zacks Investment Research

Published 3 hours ago

Likes 0

Comments 0

Shares 0

News ID #2,312

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

Comments

User Menu